CA2692698A1 - Conservation d'une structure de peptides secondaire - Google Patents

Conservation d'une structure de peptides secondaire Download PDF

Info

Publication number
CA2692698A1
CA2692698A1 CA 2692698 CA2692698A CA2692698A1 CA 2692698 A1 CA2692698 A1 CA 2692698A1 CA 2692698 CA2692698 CA 2692698 CA 2692698 A CA2692698 A CA 2692698A CA 2692698 A1 CA2692698 A1 CA 2692698A1
Authority
CA
Canada
Prior art keywords
phe
lys
ala
asp
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2692698
Other languages
English (en)
Inventor
Thitiwan Buranachokpaisan
Feng Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2692698A1 publication Critical patent/CA2692698A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA 2692698 2007-07-09 2008-07-09 Conservation d'une structure de peptides secondaire Abandoned CA2692698A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US94852507P 2007-07-09 2007-07-09
US60/948,525 2007-07-09
US95548007P 2007-08-13 2007-08-13
US60/955,480 2007-08-13
PCT/US2008/069456 WO2009009552A2 (fr) 2007-07-09 2008-07-09 Conservation d'une structure de peptides secondaire

Publications (1)

Publication Number Publication Date
CA2692698A1 true CA2692698A1 (fr) 2009-01-15

Family

ID=40042858

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2692698 Abandoned CA2692698A1 (fr) 2007-07-09 2008-07-09 Conservation d'une structure de peptides secondaire

Country Status (10)

Country Link
US (1) US20100331264A1 (fr)
EP (1) EP2167133A2 (fr)
JP (1) JP2010533195A (fr)
KR (1) KR20100028632A (fr)
CN (1) CN101730548A (fr)
AU (1) AU2008275170A1 (fr)
BR (1) BRPI0813698A2 (fr)
CA (1) CA2692698A1 (fr)
RU (1) RU2010104042A (fr)
WO (1) WO2009009552A2 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69530196T2 (de) * 1994-06-02 2003-11-20 Elan Drug Delivery Ltd Methode zum verhindern der aggregation von proteinen/peptiden bei rehydratation oder auftauen
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity

Also Published As

Publication number Publication date
US20100331264A1 (en) 2010-12-30
AU2008275170A1 (en) 2009-01-15
WO2009009552A2 (fr) 2009-01-15
BRPI0813698A2 (pt) 2014-12-30
JP2010533195A (ja) 2010-10-21
KR20100028632A (ko) 2010-03-12
RU2010104042A (ru) 2011-08-20
EP2167133A2 (fr) 2010-03-31
CN101730548A (zh) 2010-06-09
WO2009009552A3 (fr) 2009-03-12

Similar Documents

Publication Publication Date Title
TWI606838B (zh) 達托黴素（ｄａｐｔｏｍｙｃｉｎ）組合物及相關方法
TWI764996B (zh) 含西里帕格之醫藥組成物
JP4948410B2 (ja) Ｉｌ−１アンタゴニスト製剤
EP2723323B1 (fr) Lyophilisation d'agent tensioactif pulmonaire liposomal synthétique
AU2003248692B2 (en) Antifungal parenteral products
CN102772787A (zh) 促胰岛素肽的稳定制剂
JP2007045841A (ja) ヒト成長ホルモン水性製剤
BRPI0921429B1 (pt) Formulação farmacêutica liofilizada estável, e, método para preparar um fator liofilizado estável
JP2015518866A (ja) デガレリクスの製造
WO1997035882A1 (fr) Compositions lyophilisees de peptides tensioactifs pulmonaires
JP2020511440A (ja) 液体医薬組成物
JP2022547162A (ja) 抗ＩＬ－２３ｐ１９抗体製剤
JP2020511443A (ja) 液体医薬組成物
CN113382714A (zh) 胶原酶制剂及其制备方法
WO2020160083A1 (fr) Procédé de préparation de compositions injectables de fosaprépitant diméglumine présentant une stabilité au stockage améliorée
CA2601279A1 (fr) Formulation pour aviptadil
CN102665682A (zh) 包含igf-1蛋白、缓冲剂和张力剂的药物组合物
JP6869255B2 (ja) 凍結医薬製剤およびその使用
CN114514033A (zh) 药物开发
CA2692698A1 (fr) Conservation d'une structure de peptides secondaire
CN114224851A (zh) 一种人白细胞介素10-Fc融合蛋白的冻干粉制剂及制备方法
JP2021183644A (ja) カルベトシンの安定的鼻腔内製剤
WO2001000230A1 (fr) Composition medicamenteuse contenant une superoxyde dismutase modifiee par lecithine
EP3802805A1 (fr) Compositions pharmaceutiques pour traiter une déficience en sphingomyélinase acide
US11980655B2 (en) Methods of treatment with stable liquid formulations of glucagon-like peptide 1 or analogues thereof

Legal Events

Date Code Title Description
FZDE Discontinued